5-HT3 antagonist ondansetron increases apoE secretion by modulating the LXR-ABCA1 pathway

Motoko Shinohara, Mitsuru Shinohara, Jing Zhao, Yuan Fu, Chia-Chen Liu, Takahisa Kanekiyo, Guojun D Bu

Research output: Contribution to journalArticle

Abstract

Apolipoprotein E (apoE) is linked to the risk for Alzheimer’s disease (AD) and thus has been suggested to be an important therapeutic target. In our drug screening effort, we identified Ondansetron (OS), an FDA-approved 5-HT3 antagonist, as an apoE-modulating drug. OS at low micromolar concentrations significantly increased apoE secretion from immortalized astrocytes and primary astrocytes derived from apoE3 and apoE4-targeted replacement mice without generating cellular toxicity. Other 5-HT3 antagonists also had similar effects as OS, though their effects were milder and required higher concentrations. Antagonists for other 5-HT receptors did not increase apoE secretion. OS also increased mRNA and protein levels of the ATB-binding cassette protein A1 (ABCA1), which is involved in lipidation and secretion of apoE. Accordingly, OS increased high molecular weight apoE. Moreover, the liver X receptor (LXR) and ABCA1 antagonists blocked the OS-induced increase of apoE secretion, indicating that the LXR-ABCA1 pathway is involved in the OS-mediated facilitation of apoE secretion from astrocytes. The effects of OS on apoE and ABCA1 were also observed in human astrocytes derived from induced pluripotent stem cells (iPSC) carrying the APOE ε3/ε3 and APOE ε4/ε4 genotypes. Oral administration of OS at clinically-relevant doses affected apoE levels in the liver, though the effects in the brain were not observed. Collectively, though further studies are needed to probe its effects in vivo, OS could be a potential therapeutic drug for AD by modulating poE metabolism through the LXR-ABCA1 pathway.

Original languageEnglish (US)
Article number1488
JournalInternational Journal of Molecular Sciences
Volume20
Issue number6
DOIs
StatePublished - Mar 2 2019

Fingerprint

Serotonin 5-HT3 Receptor Antagonists
Ondansetron
secretions
Apolipoproteins E
liver
Liver
Carrier Proteins
proteins
Proteins
drugs
Astrocytes
stem cells
metabolism
Alzheimer Disease
toxicity
brain
mice
Liver X Receptors
Apolipoproteins
Apolipoprotein E3

Keywords

  • ABCA1
  • Alzheimer’s disease
  • ApoE
  • Astrocytes
  • LXR
  • Ondansetron

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry

Cite this

5-HT3 antagonist ondansetron increases apoE secretion by modulating the LXR-ABCA1 pathway. / Shinohara, Motoko; Shinohara, Mitsuru; Zhao, Jing; Fu, Yuan; Liu, Chia-Chen; Kanekiyo, Takahisa; Bu, Guojun D.

In: International Journal of Molecular Sciences, Vol. 20, No. 6, 1488, 02.03.2019.

Research output: Contribution to journalArticle

@article{d78ff9832d804ebf9739c5c14236e2d1,
title = "5-HT3 antagonist ondansetron increases apoE secretion by modulating the LXR-ABCA1 pathway",
abstract = "Apolipoprotein E (apoE) is linked to the risk for Alzheimer’s disease (AD) and thus has been suggested to be an important therapeutic target. In our drug screening effort, we identified Ondansetron (OS), an FDA-approved 5-HT3 antagonist, as an apoE-modulating drug. OS at low micromolar concentrations significantly increased apoE secretion from immortalized astrocytes and primary astrocytes derived from apoE3 and apoE4-targeted replacement mice without generating cellular toxicity. Other 5-HT3 antagonists also had similar effects as OS, though their effects were milder and required higher concentrations. Antagonists for other 5-HT receptors did not increase apoE secretion. OS also increased mRNA and protein levels of the ATB-binding cassette protein A1 (ABCA1), which is involved in lipidation and secretion of apoE. Accordingly, OS increased high molecular weight apoE. Moreover, the liver X receptor (LXR) and ABCA1 antagonists blocked the OS-induced increase of apoE secretion, indicating that the LXR-ABCA1 pathway is involved in the OS-mediated facilitation of apoE secretion from astrocytes. The effects of OS on apoE and ABCA1 were also observed in human astrocytes derived from induced pluripotent stem cells (iPSC) carrying the APOE ε3/ε3 and APOE ε4/ε4 genotypes. Oral administration of OS at clinically-relevant doses affected apoE levels in the liver, though the effects in the brain were not observed. Collectively, though further studies are needed to probe its effects in vivo, OS could be a potential therapeutic drug for AD by modulating poE metabolism through the LXR-ABCA1 pathway.",
keywords = "ABCA1, Alzheimer’s disease, ApoE, Astrocytes, LXR, Ondansetron",
author = "Motoko Shinohara and Mitsuru Shinohara and Jing Zhao and Yuan Fu and Chia-Chen Liu and Takahisa Kanekiyo and Bu, {Guojun D}",
year = "2019",
month = "3",
day = "2",
doi = "10.3390/ijms20061488",
language = "English (US)",
volume = "20",
journal = "International Journal of Molecular Sciences",
issn = "1661-6596",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "6",

}

TY - JOUR

T1 - 5-HT3 antagonist ondansetron increases apoE secretion by modulating the LXR-ABCA1 pathway

AU - Shinohara, Motoko

AU - Shinohara, Mitsuru

AU - Zhao, Jing

AU - Fu, Yuan

AU - Liu, Chia-Chen

AU - Kanekiyo, Takahisa

AU - Bu, Guojun D

PY - 2019/3/2

Y1 - 2019/3/2

N2 - Apolipoprotein E (apoE) is linked to the risk for Alzheimer’s disease (AD) and thus has been suggested to be an important therapeutic target. In our drug screening effort, we identified Ondansetron (OS), an FDA-approved 5-HT3 antagonist, as an apoE-modulating drug. OS at low micromolar concentrations significantly increased apoE secretion from immortalized astrocytes and primary astrocytes derived from apoE3 and apoE4-targeted replacement mice without generating cellular toxicity. Other 5-HT3 antagonists also had similar effects as OS, though their effects were milder and required higher concentrations. Antagonists for other 5-HT receptors did not increase apoE secretion. OS also increased mRNA and protein levels of the ATB-binding cassette protein A1 (ABCA1), which is involved in lipidation and secretion of apoE. Accordingly, OS increased high molecular weight apoE. Moreover, the liver X receptor (LXR) and ABCA1 antagonists blocked the OS-induced increase of apoE secretion, indicating that the LXR-ABCA1 pathway is involved in the OS-mediated facilitation of apoE secretion from astrocytes. The effects of OS on apoE and ABCA1 were also observed in human astrocytes derived from induced pluripotent stem cells (iPSC) carrying the APOE ε3/ε3 and APOE ε4/ε4 genotypes. Oral administration of OS at clinically-relevant doses affected apoE levels in the liver, though the effects in the brain were not observed. Collectively, though further studies are needed to probe its effects in vivo, OS could be a potential therapeutic drug for AD by modulating poE metabolism through the LXR-ABCA1 pathway.

AB - Apolipoprotein E (apoE) is linked to the risk for Alzheimer’s disease (AD) and thus has been suggested to be an important therapeutic target. In our drug screening effort, we identified Ondansetron (OS), an FDA-approved 5-HT3 antagonist, as an apoE-modulating drug. OS at low micromolar concentrations significantly increased apoE secretion from immortalized astrocytes and primary astrocytes derived from apoE3 and apoE4-targeted replacement mice without generating cellular toxicity. Other 5-HT3 antagonists also had similar effects as OS, though their effects were milder and required higher concentrations. Antagonists for other 5-HT receptors did not increase apoE secretion. OS also increased mRNA and protein levels of the ATB-binding cassette protein A1 (ABCA1), which is involved in lipidation and secretion of apoE. Accordingly, OS increased high molecular weight apoE. Moreover, the liver X receptor (LXR) and ABCA1 antagonists blocked the OS-induced increase of apoE secretion, indicating that the LXR-ABCA1 pathway is involved in the OS-mediated facilitation of apoE secretion from astrocytes. The effects of OS on apoE and ABCA1 were also observed in human astrocytes derived from induced pluripotent stem cells (iPSC) carrying the APOE ε3/ε3 and APOE ε4/ε4 genotypes. Oral administration of OS at clinically-relevant doses affected apoE levels in the liver, though the effects in the brain were not observed. Collectively, though further studies are needed to probe its effects in vivo, OS could be a potential therapeutic drug for AD by modulating poE metabolism through the LXR-ABCA1 pathway.

KW - ABCA1

KW - Alzheimer’s disease

KW - ApoE

KW - Astrocytes

KW - LXR

KW - Ondansetron

UR - http://www.scopus.com/inward/record.url?scp=85064229404&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064229404&partnerID=8YFLogxK

U2 - 10.3390/ijms20061488

DO - 10.3390/ijms20061488

M3 - Article

VL - 20

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 6

M1 - 1488

ER -